Clinical Trial Detail

NCT ID NCT04165031
Title A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Advanced Solid Tumor

Therapies

Cetuximab + LY3499446

Erlotinib + LY3499446

LY3499446

Abemaciclib + LY3499446

Docetaxel

Age Groups: senior adult

No variant requirements are available.